Biohaven Ltd. (BHVN) FY2025 10-K Annual Report
Biohaven Ltd. (BHVN) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 2, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Biohaven Ltd. FY2025 10-K Analysis
Business Overview
- • Core business: Biopharmaceutical development focused on neurological therapies, notably troriluzole
- • New financing structure: $250M initial senior secured notes plus up to $350M contingent tranches linked to regulatory approvals
- • Strategic shift to revenue-based funding with royalty-like payments of 6.25%+ on global net sales of troriluzole
- • Most notable metric: $250 million proceeds received from First Notes in April 2025 under Note Purchase Agreement
- • Unique feature: Complex milestone, revenue payment caps, and call/put options tied to FDA/EMA approval timelines and sales benchmarks
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in the provided text
- • No segment performance or cash flow information reported
- • No management outlook, guidance, or key emerging risks mentioned
- • Text focuses on industry data sources, estimates, and trademark notices
Risk Factors
- • Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement
- • Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization
- • Operational risk: One-time $42.7M cash milestone payment to Knopp in January 2026 related to 2025 Additional Consideration under Knopp Amendment
- • Competitive risk: Royalty buyback of $867.5M milestone payments to Knopp reduces future payments but exposes to mid-single digit flat royalty on Kv7 programs
- • Financial risk: Liquidity pressure with net operating loss and $609.4M cash used in operations in 2025 despite $230M cash and $89.2M marketable securities on hand
Biohaven Ltd. FY2025 Key Financial MetricsXBRL
Net Income
-$739M
▲ +12.7% YoY
ROE
-1418.8%
▼ -121895bp YoY
Total Assets
$451M
▼ -26.6% YoY
EPS (Diluted)
$-6.86
▲ +26.1% YoY
Operating Cash Flow
-$609M
▼ -4.6% YoY
Source: XBRL data from Biohaven Ltd. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Biohaven Ltd.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.